A detailed history of Jacobs Levy Equity Management, Inc transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 251,562 shares of TYRA stock, worth $3.91 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
251,562
Previous 395,299 36.36%
Holding current value
$3.91 Million
Previous $3.78 Million 6.98%
% of portfolio
0.01%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 17, 2025

SELL
$9.59 - $13.99 $1.38 Million - $2.01 Million
-143,737 Reduced 36.36%
251,562 $3.52 Million
Q2 2025

Aug 14, 2025

BUY
$7.06 - $10.86 $660,095 - $1.02 Million
93,498 Added 30.98%
395,299 $3.78 Million
Q1 2025

May 15, 2025

BUY
$9.3 - $16.73 $535,270 - $962,911
57,556 Added 23.56%
301,801 $2.81 Million
Q4 2024

Feb 14, 2025

BUY
$13.9 - $28.61 $3.4 Million - $6.99 Million
244,245 New
244,245 $3.4 Million

Others Institutions Holding TYRA

About Tyra Biosciences, Inc.


  • Ticker TYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,973,600
  • Market Cap $652M
  • Description
  • Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...
More about TYRA
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.